Toward a Life Without Daily Insulin Injections

Over 500,000 people worldwide are affected by unstable Type 1 Diabetes. BIOPI is developing an implantable bioartificial pancreas that encapsulates insulin-secreting cells inside advanced 3D hydrogels. Our device aims to deliver autonomous glucose regulation without immunosuppressive drugs, using scalable non-human cell sources for long-term durability.

Discover Our Breakthrough Join Our Mission

Revolutionary Innovation

The BIOPI Difference

BIOPI is building a new class of diabetes therapy: a fully implantable device that protects insulin-secreting cells inside a patented 3D matrix. Our technology enhances cell survival, eliminates the need for immunosuppression, and opens the door to large scale treatment thanks to non-human cell compatibility.

Advanced Immunoprotection

Hydrogels shield cells from rejection while allowing essential nutrient and oxygen exchange.

Optimized Microenvironment

Our architecture ensures long-term viability and efficient insulin secretion.

Dynamic Glucose Sensing

Encapsulated cells autonomously sense glucose and regulate insulin release in real time.

Sustainable Design

Engineered for long-term functionality with minimal/easy maintenance.

Transformative Impact

  • Autonomous glucose regulation without daily injections
  • No lifelong immunosuppressive drugs
  • Long term vision compatible with scalable stem cell technologies
  • Reduced hypoglycemia and improved metabolic stability
  • Designed for durability, safety, and patient quality of life

Disclaimer: Investigational device in pre-clinical phase. Functional prototype developed; not yet available for sale.

How Our Bioartificial Pancreas Works

1. Cell Sourcing

High quality insulin-secreting cells from certified sources. Currently: donor pancreatic islets for preclinical and early clinical testing. Future: stem cells for large-scale, renewable production.

2. Innovative Encapsulation

Patented 3D hydrogels create a protective, biocompatible microenvironment.

3. Nutrient Optimization

Advanced matrix design sustains oxygen and nutrient delivery.

4. Responsive Regulation

Encapsulated cells autonomously sense glucose and secrete insulin.

Milestones, Team & Labs

Key Milestones

  • 2024 Deep Impact Award - Jury Special Prize
  • 2025 Selected Top 5 Medtech/Biotech at Tech&Fest
  • Ongoing Preclinical testing of functional prototype
  • Ongoing Strategic partnerships with top institutions
Watch Award Presentation

Our Expert Team

A multidisciplinary team of researchers, physicians, and engineers specialized in biomaterials, cell therapy, and implantable medical devices.

Portrait of Ibrahim Shalayel, Project Leader at BIOPI
Ibrahim Shalayel
Project Leader & Entrepreneur

Collaborating Laboratories

Key Partners

Empowered by Leading Partners

Frequently Asked Questions

BIOPI offers a new generation of bioartificial pancreas that protects insulin secreting cells without immunosuppressive drugs, thanks to a patented 3D hydrogel system that creates a safe environment for long term cell survival. Our design enhances oxygenation, improves glucose responsiveness, and opens the door to scalable cell sources, enabling a realistic path toward a durable and donor independent treatment for Type 1 Diabetes.

We are now entering preclinical testing using donor pancreatic islets to demonstrate safety and efficacy in vivo. In parallel, we are preparing the integration of stem-cell–derived insulin-producing cells with our encapsulation technology to support future therapeutic expansion.

BIOPI aims to restore natural, autonomous insulin regulation, removing the need for daily injections, reducing the burden of glucose monitoring, and minimizing the risks of hypoglycemia and long term complications. BIOPI seeks to help patients regain stability, freedom, and a far better quality of life.

Clinical trials will begin once preclinical validation and regulatory preparations are complete. BIOPI is currently advancing through in-vivo testing and device optimization, with first interactions with regulatory agencies planned before entering human studies. We will share updates publicly as soon as trial timelines are confirmed.

Connect With Us

We welcome collaborations with investors, industry partners, and research institutions. Based in Grenoble, France. Hosted at TIMC Laboratory (INSyGHT Team).

contact@bio-pi.com
Download Our Flyer
Linksium logo More Info

Contacting us means you're interested in our updates. Your privacy is our priority - no data sharing.